| Bioactivity | Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3]. |
| Name | Atazanavir |
| CAS | 198904-31-3 |
| Formula | C38H52N6O7 |
| Molar Mass | 704.86 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Atazanavir
CAS: 198904-31-3 F: C38H52N6O7 W: 704.86
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.